

**SMS Lifesciences India Limited**

Registered & Corporate Office :
Plot No. 19-III, Road No. 71,
Opp. Bharatiya Vidya Bhavan Public School,
Jubilee Hills, Hyderabad - 500 096, Telangana, INDIA.
Tel : +91-040-6628 8888, Fax : +91-40-2355 1401
CIN : L74930TG2006PLC050223
Email : info@smslife.in, Website : www.smslife.in

July 16, 2025

To

BSE Limited,

Listing Department, P J Towers,
Dalal Street,
Mumbai – 400 001.

Scrip Code: 540679

Through: BSE Listing Center

National Stock Exchange of India Limited,

Listing Department, "Exchange Plaza",
Bandra-Kurla Complex, Bandra (E),
Mumbai - 400 051.

Trading Symbol: SMSLIFE

Through: NEAPS Portal

SUB: INTIMATION REGARDING RECEIPT OF ESTABLISHMENT INSPECTION REPORT.

Ref: Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

Dear Sir/ Madam,

In continuation to our [earlier communication dated May 9, 2025](#) regarding the USFDA inspection, we are pleased to inform that the Company has received **Establishment Inspection Report (EIR)** with a Voluntary Action Indicated (VAI) status from the U.S. Food and Drug Administration for our API manufacturing facility (Unit 1) located at Kazipally, Telangana, on July 15, 2025 at 09.37 pm.

The receipt of EIR reaffirms the Company's commitment to maintaining global quality standards and enables access to the regulated US market and other highly regulated global markets.

Kindly take the same on record and suitably disseminate it to all concerned.

For SMS Lifesciences India Limited

Trupti Ranjan Mohanty

Company Secretary

Memb No. FCS 13407

PLEASE NOTE THAT THIS DISCLOSURE IS BEING SUBMITTED WITHIN 24 HOURS OF RECEIPT OF THE EMAIL CONFIRMATION, PURSUANT TO SEBI CIRCULAR NO. SEBI/HO/CFD/CFD-POD-2/CIR/P/2024/185 DATED DECEMBER 31, 2024.